Divestment of portfolio of branded and generic products to Strides entities

Aspen is pleased to announce that certain of its wholly… 继续阅读Divestment of portfolio of branded and generic products to Strides entities

Cautionary Announcement

Shareholders are advised that Aspen is currently engage… 继续阅读Cautionary Announcement

Divestment of South African Business Unit to Litha

Aspen is pleased to announce that Pharmacare Limited (“… 继续阅读Divestment of South African Business Unit to Litha

Gauteng Premier’s visit to Aspen is set to boost export growth

Clayville, Johannesburg – JSE Limited listed Aspen Phar… 继续阅读Gauteng Premier’s visit to Aspen is set to boost export growth

Aspen opposes violent attacks directed at fellow African migrants

Statement by Stephen Saad, Group CEO, Aspen Pharmacare … 继续阅读Aspen opposes violent attacks directed at fellow African migrants

GSK announces completion of the sale of half its stake in Aspen

GlaxoSmithKline (“GSK”) has announced the completion of… 继续阅读GSK announces completion of the sale of half its stake in Aspen

Aspen’s half-year gross revenue surges by 47% to R19 billion

Aspen’s half-year gross revenue surges by 47% to R19 bi… 继续阅读Aspen’s half-year gross revenue surges by 47% to R19 billion

Acquisition of rights to an anti-coagulant product from Novartis

Aspen is pleased to announce that Aspen Global Incorpor… 继续阅读Acquisition of rights to an anti-coagulant product from Novartis

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.